Roche’s entrectinib for gene fusion-positive cancers has shown promising results in a range of paediatric cancers in an early-stage trial, earning it a spotlight position at a pre-ASCO pres
The FDA has approved Akebia Therapeutics’ vadadustat as a treatment for anaemia caused by chronic kidney disease (CKD) in dialysis patients, becoming the first rival to GS